Safe treatment of lung squamous cell carcinoma with nanoparticle albumin-bound Paclitaxel in a patient with a previous hypersensitivity reaction after docetaxel administration
Uenami, T.; Mori, M.; Ageshio, F.; Kagawa, H.; Matsui, H.; Satomi, A.; Niinaka, M.; Kimura, H.; Yano, Y.; Yoneda, T.; Yamaguchi, T.; Yokota, S.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 42(3): 375-377
2015
ISSN/ISBN: 0385-0684 PMID: 25812512 Document Number: 685012
A 61-year-old man was diagnosed with lung squamous cell carcinoma in the lower lobe of the right lung. He had received first-line chemotherapy consisting of cisplatin and docetaxel (DTX); however, an allergic/hypersensitivity reaction occurred shortly after administration of the second course of DTX. Thirty-nine months later, he received nanoparticle albumin-bound paclitaxel (nab-PTX) as sixth-line chemotherapy, which did not produce a hypersensitivity reaction. Hypersensitivity after DTX administration may have been due to the DTX vehicle. Therefore, nab-PTX administered under close supervision is a valid therapeutic option in similar cases.